This article, and the accompanying one by Dr. Carpenter, discuss the benefits and risks associated with taking patients with schizophrenia off medications for research purposes. This article reviews the concept that at least some forms of schizophrenia are progressive. Evidence for this view is provided by studies examining the impact of early intervention with antipsychotic medications on the long-term morbidity of schizophrenia, as well as the few studies examining the long-term risks of discontinuing antipsychotic medications in patients with schizophrenia. While there is evidence that early intervention improves the long-term course of the illness, it is not known whether withdrawal of antipsychotic medications increases long-term morbidity. This is an area where further information is needed for clinical practice and research.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1093/schbul/23.1.3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Medication adherence and attitudes in adolescent psychiatry: Key influences.
Clin Child Psychol Psychiatry
January 2025
Department of Clinical Pharmacy, Hacettepe University Faculty of Pharmacy, Türkiye.
Adolescents with mental illnesses often struggle with adhering to prescribed medication regimens. This study investigates how patient perceptions influence medication adherence among adolescents with psychiatric disorders. It also examines the role of patient characteristics and medication-related factors on adherence and attitudes.
View Article and Find Full Text PDFImproving Medication Adherence in Psychiatric Patients With a Medication Adherence Program.
J Am Psychiatr Nurses Assoc
January 2025
Whitney Peterson, DNP, MSN-Ed., RN.
Background: It's estimated that over 50% of patients prescribed antipsychotic medication are nonadherent to the prescribed treatment. Medication nonadherence impedes the patient's safety, leads to relapse, and the need for rehospitalization. Thus bolstering the importance of routine nursing follow-up interventions to improve adherence rates in patient with SMI.
View Article and Find Full Text PDFTrends in Formulary Restrictions for Long-Acting Injectable Antipsychotic Medications Among Medicare Drug Plans, 2019-2023.
Psychiatr Serv
January 2025
Department of Psychiatry and Behavioral Neuroscience (Bunting, Gray), Department of Pharmacy (Gray), and Pritzker School of Medicine (Chalmers), University of Chicago, Chicago; Department of Psychiatry and Behavioral Sciences, Emory University School of Medicine, Atlanta (Cotes); Department of Psychiatry, University of Washington, Seattle (Chalmers); Department of Health Management and Policy, School of Public Health, University of Michigan, Ann Arbor (Nguyen).
Objective: Long-acting injectable antipsychotics (LAIAPs) enable safe and effective long-term management of chronic psychotic disorders but are underused in clinical practice. The authors examined whether Medicare formulary restrictions (prior authorization [PA] or step therapy) impose barriers to LAIAP uptake.
Methods: The authors analyzed formulary restrictions and patient cost-sharing for several LAIAPs and estimated the percentage of plans (N=2,494 were available per year) applying formulary restrictions.
Pharmacotherapy for Tourette Syndrome.
Psychiatr Clin North Am
March 2025
Pediatric Psychiatry OCD and Tic Disorders Program, Department of Psychiatry, Massachusetts General Hospital, 185 Cambridge Street, Suite 2000, Boston, MA 02114, USA. Electronic address:
Tourette syndrome (TS) is associated with dysregulated cortico-striatal-thalamo-cortical neural circuitry, of which the primary implicated neurotransmitters include dopamine, glutamate, and gamma-aminobutyric acid. Pharmacologic intervention for tics should be considered when tics are causing psychological, functional, or physical impairment, and behavioral treatment is either inaccessible or ineffective. Only 3 medications have Food and Drug Administration approval for TS, including 2 typical antipsychotics (pimozide and haloperidol) and 1 atypical antipsychotic (aripiprazole).
View Article and Find Full Text PDFDistribution and correlates of long-acting injectable antipsychotic use among community mental health center patients.
Psychiatry Res
January 2025
South Carolina Department of Mental Health, 220 Executive Dr, Greer, SC 29651, United States; Department of Neuropsychiatry and Behavioral Science, University of South Carolina School of Medicine, 15 Medical Park, Suite 301, Columbia, SC 29203, United States.
Although long-acting injectable antipsychotics (LAIs) are an important pharmaceutical option in the management of schizophrenia and related disorders, little is known about patient characteristics related to LAI use in real-world outpatient settings. We analyzed electronic medical records from 41,401 patients who received psychiatric services from one of 16 regional mental health centers operated by the South Carolina Department of Mental Health in 2022. We compared the use of first- and second-generation LAIs and oral antipsychotics by sociodemographic (age, gender, race/ethnicity, zip code, payment source) and clinical characteristics (psychiatric diagnoses, service use).
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!